Levels of 17β-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26401932
DOI
10.3233/jad-142898
PII: JAD142898
Knihovny.cz E-resources
- Keywords
- 17β-HSD10, Alzheimer’s disease, amyloid-β peptides, biomarker, cerebrospinal fluid,
- MeSH
- 3-Hydroxyacyl CoA Dehydrogenases cerebrospinal fluid MeSH
- Amyloid beta-Peptides cerebrospinal fluid MeSH
- Dementia cerebrospinal fluid classification MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Cognitive Dysfunction cerebrospinal fluid MeSH
- Middle Aged MeSH
- Humans MeSH
- Peptide Fragments cerebrospinal fluid MeSH
- tau Proteins cerebrospinal fluid MeSH
- ROC Curve MeSH
- Aged MeSH
- Age Factors MeSH
- Mental Status Schedule MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 3-Hydroxyacyl CoA Dehydrogenases MeSH
- amyloid beta-protein (1-40) MeSH Browser
- Amyloid beta-Peptides MeSH
- HSD17B10 protein, human MeSH Browser
- Peptide Fragments MeSH
- tau Proteins MeSH
BACKGROUND: Overexpression of the mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10, which is also known as the intracellular amyloid-β peptide (Aβ) binding protein) is observed in cortical or hippocampal regions of patients with Alzheimer's disease (AD). It appears that 17β-HSD10 may play a role in the pathogenesis of AD. OBJECTIVE: We investigated the possibility that levels of 17β-HSD10 in cerebrospinal fluid could be a prospective biomarker of AD. METHODS: We estimated the enzyme levels in 161 people (15 non-demented controls, 52 people with mild cognitive impairment (MCI), 35 people with probable AD, or 59 people with other types of dementia) and compared them with those of Aβ(1- 42), tau, and phospho-tau. RESULTS: We found significantly higher levels of 17β-HSD10 in people with MCI due to AD (to 109.9% ), with AD (to 120.0% ), or with other types of dementia (to 110.9% ) when compared to the control group. The sensitivity of the new biomarker to AD was 80.0% , and the specificity was 73.3% (compared to controls) or 52.5-59.1% (compared to other types of dementia). Results of multiple linear regression and of correlation analysis revealed AD-mediated changes in links between 17β-HSD10 and Mini Mental State Examination score. CONCLUSION: It seems that changes in 17β-HSD10 start many years before symptom onset, analogous to those in Aβ1 - 42, tau, or phospho-tau and that the levels are a relatively highly sensitive but unfortunately less specific biomarker of AD. A role of 17β-HSD10 overexpression in AD is discussed.
Institute of Computer Science Academy of Sciences Praha 8 Czech Republic
International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic
References provided by Crossref.org
Interactions of 17β-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease
